Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Early PD (diagnosed within 3 years) | TEMPO-2 Study - Cerevel Therapeutics

Flexible-Dose Trial of Tavapadon in Early Parkinson's Disease


EvergreenHealth's Booth Gardner Parkinson's Care Center is conducting a phase 3, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

Full Title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease

Currently Enrolling

Who may be eligible to participate?
Male or female, age 40 to 80 years who have been diagnosed with Parkinson's disease (PD) within 3 years of the screening visit. Other inclusion/exclusion criteria apply.

What does participation involve?

  • Subjects will be randomized to receive either tavapadon or placebo, once daily.
  • The trial will include a Screening Period (maximum of 4 weeks), a 27-week Treatment Period, a 10-day Safety/Withdrawal Assessment Period, and a 20-day Safety Follow-up Period
  • Each subject will participate in the study for up to approximately 35 weeks.

EvergreenHealth's Study ID
CVL-751-PD-002 ID

IRB Protocol Number
Principal Investigator(s)
Daniel Burdick, MD

Clinical Trial Categories

  • Parkinson's Disease
Cerevel Therapeutics
EvergreenHealth Research Services at 425-899-5385


  • EvergreenHealth Clinical Trials
    12039 NE 128th Street, Suite 300
    Kirkland, WA 98034
    Main: 425-899-5385

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form